📰 Wolf Research News
Page 7 - Wolf Research News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Wolf Research. Real-time updates on events, politics, business and more.
August 11, 2023
Stocks are lower to end the week. The S&P 500 is on track for a small weekly decline.
August 11, 2023
Operator: Good afternoon ladies and gentlemen and welcome to the Beacon Second Quarter 2023 Earnings Call. My name is Sam and Ill be your coordinator for today.
August 4, 2023
Operator: Good morning and welcome to Hasbro’s Second Quarter 2023 Earnings Conference Call. At this time all parties will be in listen-only mode. [Operator Instructions].
August 4, 2023
Microchip Technology Incorporated (NASDAQ:MCHP) Q1 2024 Earnings Call Transcript August 3, 2023 Operator: Welcome to the First Quarter Fiscal 2024 Conference Call. I will now turn the call over to today’s host Eric Bjornholt, Chief Financial Officer of Microchip. You may begin. Eric Bjornholt: Good afternoon everybody. During the course of this conference call, we […]
August 4, 2023
Expedia Group, Inc. (NASDAQ:EXPE) Q2 2023 Earnings Call Transcript August 3, 2023 Expedia Group, Inc. beats earnings expectations. Reported EPS is $2.89, expectations were $2.32. Operator: Good day, everyone, and welcome to the Expedia Group Q2 2023 Financial Results Teleconference. My name is Colby, and I’ll be the operator for today’s call. [Operator Instructions] For […]
July 30, 2023
Operator: Ladies and gentlemen, greetings, and welcome to the Tri Pointe Homes Second Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.
July 7, 2023
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
July 7, 2023
Cholesterol Efflux Mediator™VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys filtration system in patients with glomerular...
July 7, 2023
Shares of ZyVersa Therapeutics, Inc. (ZVSA) are up 11% on Friday after the announcement that European Patent Office granted a patent (Patent Number EP 2 836 221) for the company's Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease.
July 7, 2023
Cholesterol Efflux Mediator™ VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys filtration system in patients with glomerular diseases, including diabetic